Oncology R&D Boosts Korean Clinical Trials In 2015
This article was originally published in PharmAsia News
Executive Summary
With South Korean pharma firms and drug developers striving to turn into innovators, the number of clinical trials approved by regulatory authorities climbed last year, led by studies for cancer therapies, particularly those acting on the immune system, one of the most active research areas globally.
You may also be interested in...
Korea Govt Partners With J&J To Bring In Local JLABS Site
In collaboration with the national health ministry, J&J’s JLAB program is coming to South Korea as its third destination in Asia, underscoring the country’s increasing need to access multinationals’ know-how and its growing impact on the global biotech landscape and innovation.
Could ASEAN Become Next Priority For Korean Pharma Firms?
Southeast Asia has so far not been a priority market for South Korean pharma firms, largely because of challenges such as access and affordability for patients. But a Deloitte executive suggested at a recent seminar that technology-based medicines, for example using next-generation formulation technologies, could be an initial focus for Korean firms looking to enter the rapidly growing ASEAN grouping.
Korean Biotech Roundup: String Of Positive R&D Developments Outweighs Some Setbacks
The South Korean biotech space has been marked by multiple positive R&D developments and pipeline and partnering progress in recent months, more than outweighing some other setbacks for the rapidly developing sector.